Red Biotechnology Global Market Report 2024

The red biotechnology market size has grown rapidly in recent years. It will grow from $509.71 billion in 2023 to $566.28 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth during the historical period can be attributed to advancements in genetic engineering, stem cell research, the growth of biotech startups, regulatory frameworks, biotech funding, and investment.

The red biotechnology market size is expected to see rapid growth in the next few years. It will grow to $867.2 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. In the forecast period, growth can be attributed to the expansion of personalized medicine, the aging population, investment in research and development, integration of digital health, and the expansion of healthcare infrastructure. Major trends expected include the expansion of biologics and biosimilars, integration of machine learning, development of microbiome-based therapies, focus on rare and orphan diseases, global collaboration, and partnerships.

The red biotechnology market is set to experience growth, driven by the increasing demand for personalized medicine. Personalized medicine tailors medical treatment to individual characteristics such as genetics or lifestyle to optimize effectiveness and reduce adverse effects. This demand is fueled by the potential for more effective treatments, advances in genomics, growing disease complexities, and supportive regulations. Red biotechnology facilitates the development of personalized medicines by leveraging genetic information to customize treatments based on a patient's genetic profile and disease attributes. For example, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six in 2022, as reported by the Personalized Medicine Coalition.

Leading companies in the red biotechnology sector are concentrating on developing innovative products such as biosimilars to cater to the rising demand for personalized medicine and tackle disease complexities. Biosimilars are biological products closely resembling existing approved reference biologics, offering cost-effective alternatives. For instance, in June 2022, Amgen Inc. obtained FDA approval for Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for treating adults with moderate to severe rheumatoid arthritis (RA). This milestone underscores the development of biosimilars, designed to mimic existing biological products at lower costs.

In March 2023, Ipsen Biopharmaceuticals Inc. acquired Albireo Pharma Inc. to enhance its Rare Disease portfolio with therapies for rare cholestatic liver diseases. Albireo Pharma Inc. specializes in novel bile acid modulators for orphan pediatric liver diseases, contributing to Ipsen's scientific and commercial capabilities.

Major companies operating in the red biotechnology market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Amgen Inc., Merck KGaA, Moderna Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., Vir Biotechnology, Alnylam Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, BioCryst Pharmaceuticals, Sangamo Therapeutics, Inc., Denali Therapeutics, Atara Biotherapeutics, Beam Therapeutics, Umoja Biopharma.

North America was the largest region in the red biotechnology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the red biotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the red biotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Red biotechnology, a branch of biotechnology, focuses on medical and pharmaceutical applications, utilizing biological systems and organisms to develop products and technologies for healthcare. These include pharmaceuticals, diagnostic tests, and therapies to treat diseases and enhance human health.

The main products in red biotechnology encompass monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, among others. Monoclonal antibodies, for instance, are lab-made proteins that mimic the immune system's ability to combat pathogens, finding application in targeted therapies for conditions such as cancer and autoimmune disorders. Red biotechnology spans drug discovery, animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, agricultural biotechnology, catering to end-users such as the biopharmaceutical industry, contract manufacturing organizations (CMOs), contract research organizations (CROs), research institutes, and more.

The red biotechnology market research report is one of a series of new reports that provides red biotechnology market statistics, including the red biotechnology industry global market size, regional shares, competitors with the red biotechnology market share, detailed red biotechnology market segments, market trends, and opportunities, and any further data you may need to thrive in the red biotechnology industry. These red biotechnology market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The red biotechnology market consists of sales of diagnostic testing kits, biological sensors, regenerative medicine, and antibiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.